Cyclin dependent kinase 5: A novel avenue for Alzheimer's disease

Brain Research Bulletin
Anisha S BhounsuleManisha Oza

Abstract

Alzheimer's disease (AD) is one of the most frequently encountered diseases in adults with progressive loss of memory and behavioral changes. Inspite of there being an intense research in the field of AD, only a few chemical entities exhibiting anti-AD activity make it through the clinical trials and it is thus need of an hour to develop new drugs or repurpose the existing ones for better management of Alzheimer's disease. Novel therapeutic targets can influence drug discovery in the field of AD. Cyclin Dependent Kinase 5 (Cdk5) which is a serine/threonine kinase can prove to be an upcoming beneficial target to be studied for treating AD. Cdk5 is important for development of CNS and neuron movements, however in AD pathological stimuli cause Cdk5 hyperactivation which eventually results in hyperphosphorylation of various substrates such as amyloid precursor protein, tau and many more. This review provides an insight on Cdk5 as a target for treatment of AD and discuss therapeutic candidates for targeting it.

References

Aug 8, 2014·Frontiers in Aging Neuroscience·Kelly Willemijn Menting, Jurgen A H R Claassen

❮ Previous
Next ❯

Citations

Oct 27, 2018·Molecular Nutrition & Food Research·Ming-Yao GuHyun Ok Yang
Jun 6, 2019·Expert Opinion on Drug Discovery·Juan F GonzálezJose María Sánchez-Montero
Apr 15, 2020·Current Pharmaceutical Design·Kadja Luana Chagas MonteiroEdeildo Ferreira da Silva-Júnior
May 29, 2018·Journal of Asian Natural Products Research·Cheng-Shi JiangJin-Hai Yu
Oct 24, 2018·Proceedings of the National Academy of Sciences of the United States of America·George R UhlZheng-Xiong Xi
Nov 4, 2020·European Journal of Medicinal Chemistry·Lisha WangBengt Winblad
Apr 15, 2020·ACS Chemical Neuroscience·Annamarie B AllnuttVenkata Mahidhar Yenugonda
Feb 23, 2021·Medicinal Chemistry Research : an International Journal for Rapid Communications on Design and Mechanisms of Action of Biologically Active Agents·Haizhou ZhuSwati S More
Dec 31, 2019·Biochimica Et Biophysica Acta. Molecular Cell Research·A-Ching ChaoDing-I Yang
May 18, 2021·Evidence-based Complementary and Alternative Medicine : ECAM·Teng-I Huang, Ching-Liang Hsieh
Sep 1, 2021·Contemporary Clinical Trials·Girdhari Lal Gupta, Nikita Patil Samant

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Related Papers

Molecular Neurobiology
Shu-Lei LiuJin-Tai Yu
Central Nervous System Agents in Medicinal Chemistry
S YasudaK Yamagata
BMC Medical Genetics
José Luis Vázquez-HigueraOnofre Combarros
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology
Dantao PengJiewen Zhang
© 2022 Meta ULC. All rights reserved